Hard to Treat Diseases (HTDS) Receives Equity Capital Follow Up Report

Company receives follow up report and files with Pink Sheets

LONDON, Oct. 5 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) - The
issuer's China based operating subsidiary Mellow Hope and Serbia operating
subsidiary Slavica Bio Chem are providing this news release to bring attention
to today's Pink Sheets filing. The filing called "Equity Capital Management
Update On HTDS Report" can be found on Pink Sheets HTDS listing under the tab
"Filings" or this direct link:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds
The report, amongst other things addresses the following topics: Background of
the company, Swine Flu (H1N1), Pink Sheets "Skull and Bones" to name a few.
The filing on Pink Sheets is timed to coincide and release at the same time as
this news release shortly after 2:25 pm EST.
In other company news, as previously announced with the Canadian
Pharmaceutical company continued interest and aspirations towards the cancer
research and those IP rights of HTDS Slavica Bio Chem subsidiary will shortly
be launching the cancer project and the cancer project web site
www.mindupbioresearch.com. This, together with medical posters and other
relevant information relating to the project will also be posted as a filing
on Pink Sheets and on the company corporate web site www.htdsmedical.com
shortly.
To receive regular updates on HTDS please sign up or opt in with your email
address at this link: http://www.minamargroup.com/updates/.

Safe Harbor Statement

Information in this filing may contain statements about future expectations,
plans, prospects or performance of Hard to Treat Diseases, Inc. that
constitute forward-looking statements for purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of 1995. The
words or phrases "can be", "expects", "may affect", "believed", "estimate",
"project", and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to Treat
Diseases, Inc. is not a guarantee of future performance. None of the
information in this filing constitutes or is intended as an offer to sell
securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s
actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important factors, some of
which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those
discussed in Hard to Treat Diseases, Inc.'s press releases, public filings,
and statements by Hard to Treat Diseases, Inc.'s management, including, but
not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of
its existing capital resources, Hard to Treat Diseases, Inc.'s ability to
raise additional capital to fund future operations, HTDS Corporation's ability
to repay its existing indebtedness, the uncertainties involved in estimating
market opportunities and, in identifying contracts which match Hard to Treat
Diseases, Inc.'s capability to be awarded contracts. All such forward-looking
statements are current only as of the date on which such statements were made.
Hard to Treat Diseases, Inc. does not undertake any obligation to publicly
update any forward-looking statement to reflect events or circumstances after
the date on which any such statement is made or to reflect the occurrence of
unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any investor relations matters, please
contact www.minamargroup.net/helpdesk; Investor Relations Department, (302)
357-9915 (IR), 1st Level Support Retail Clients General Inquiry,
www.minamargroup.net (IR); For (M&A) and Corporate Matters, 1-800-365-4331,
www.minamargroup.com

SOURCE Hard to Treat Diseases

For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any investor relations matters, please
contact www.minamargroup.net/helpdesk; Investor Relations Department, (302)
357-9915 (IR), 1st Level Support Retail Clients General Inquiry,
www.minamargroup.net (IR); For (M&A) and Corporate Matters, 1-800-365-4331,
www.minamargroup.com